JP2010531879A - 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法 - Google Patents
水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法 Download PDFInfo
- Publication number
- JP2010531879A JP2010531879A JP2010514847A JP2010514847A JP2010531879A JP 2010531879 A JP2010531879 A JP 2010531879A JP 2010514847 A JP2010514847 A JP 2010514847A JP 2010514847 A JP2010514847 A JP 2010514847A JP 2010531879 A JP2010531879 A JP 2010531879A
- Authority
- JP
- Japan
- Prior art keywords
- anxiety
- disorder
- group
- corresponds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical class C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 150000001875 compounds Chemical class 0.000 title claims description 127
- 230000000949 anxiolytic effect Effects 0.000 title claims description 43
- 239000003814 drug Substances 0.000 title description 59
- 229940079593 drug Drugs 0.000 title description 53
- 230000000144 pharmacologic effect Effects 0.000 title description 8
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 137
- 230000036506 anxiety Effects 0.000 claims abstract description 117
- 208000027534 Emotional disease Diseases 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 24
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 90
- 239000002249 anxiolytic agent Substances 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 23
- 208000019899 phobic disease Diseases 0.000 claims description 16
- 208000019906 panic disease Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 12
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 12
- 206010041250 Social phobia Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 9
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 9
- 206010034912 Phobia Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000015238 neurotic disease Diseases 0.000 abstract description 25
- 206010029333 Neurosis Diseases 0.000 abstract description 24
- 206010029897 Obsessive thoughts Diseases 0.000 abstract description 24
- 208000024891 symptom Diseases 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000035882 stress Effects 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 37
- 241000700159 Rattus Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 24
- 230000035622 drinking Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 230000006399 behavior Effects 0.000 description 21
- 229960003529 diazepam Drugs 0.000 description 20
- 238000002648 combination therapy Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000002354 daily effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000000049 anti-anxiety effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- -1 Diazepam® Chemical class 0.000 description 8
- 229940049706 benzodiazepine Drugs 0.000 description 8
- 150000001557 benzodiazepines Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000001624 sedative effect Effects 0.000 description 8
- 206010039897 Sedation Diseases 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 7
- 238000002483 medication Methods 0.000 description 7
- 230000036280 sedation Effects 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 206010016275 Fear Diseases 0.000 description 6
- 206010021118 Hypotonia Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 229940125713 antianxiety drug Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000036640 muscle relaxation Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 238000009093 first-line therapy Methods 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 206010027175 memory impairment Diseases 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- CYJQCYXRNNCURD-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2C1CCN(C)C2 CYJQCYXRNNCURD-UHFFFAOYSA-N 0.000 description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 102000003678 AMPA Receptors Human genes 0.000 description 3
- 108090000078 AMPA Receptors Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 229940005530 anxiolytics Drugs 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000014061 fear response Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012346 open field test Methods 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000036640 Asperger disease Diseases 0.000 description 2
- 201000006062 Asperger syndrome Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CJUOSBUQOWKEKJ-UHFFFAOYSA-N Mebhydrolin napadisilate Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 CJUOSBUQOWKEKJ-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 208000000810 Separation Anxiety Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 229940072690 valium Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- CYJQCYXRNNCURD-DGCLKSJQSA-N (4ar,9bs)-2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2[C@@H]2[C@H]1CCN(C)C2 CYJQCYXRNNCURD-DGCLKSJQSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JIHMATXQZDSUOR-UHFFFAOYSA-N 2,3,4,4a,5,5a-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2C=CC=CC2=C2C1CCNC2 JIHMATXQZDSUOR-UHFFFAOYSA-N 0.000 description 1
- BPPMRCNUQCVVFJ-UHFFFAOYSA-N 2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2=CC=CC=C2C2C1CCNC2 BPPMRCNUQCVVFJ-UHFFFAOYSA-N 0.000 description 1
- 150000008591 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles Chemical class 0.000 description 1
- MUZFLDUALLSEBH-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2=C1CCN(C)C2 MUZFLDUALLSEBH-UHFFFAOYSA-N 0.000 description 1
- TWZCZLLZJDKWFN-UHFFFAOYSA-N 2-benzyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound C1CC=2NC3=CC=CC=C3C=2CN1CC1=CC=CC=C1 TWZCZLLZJDKWFN-UHFFFAOYSA-N 0.000 description 1
- MYUAGMGKBGUWEN-UHFFFAOYSA-N 2-ethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(CC)C2 MYUAGMGKBGUWEN-UHFFFAOYSA-N 0.000 description 1
- FYHWPFXPFFPQRT-UHFFFAOYSA-N 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(C)C2 FYHWPFXPFFPQRT-UHFFFAOYSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PPRXPSDHSSUMRZ-UHFFFAOYSA-N 5-benzyl-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 PPRXPSDHSSUMRZ-UHFFFAOYSA-N 0.000 description 1
- WCTGYFWVYBPRGF-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 WCTGYFWVYBPRGF-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- JYIJLCGEBZRACV-UHFFFAOYSA-N Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 Chemical compound Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 JYIJLCGEBZRACV-UHFFFAOYSA-N 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- 241000282821 Hippopotamus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000002195 Nymphaea caerulea Nutrition 0.000 description 1
- 244000058734 Nymphaea stellata Species 0.000 description 1
- 235000016428 Nymphaea stellata Nutrition 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229950010754 dicarbine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229950000904 dorastine Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- RZXHTPCHKSYGIB-UHFFFAOYSA-N gevotroline Chemical compound C1C=2C3=CC(F)=CC=C3NC=2CCN1CCCC1=CC=CN=C1 RZXHTPCHKSYGIB-UHFFFAOYSA-N 0.000 description 1
- 229950003589 gevotroline Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000011819 intense anxiety Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940073092 klonopin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007124175/15A RU2338533C1 (ru) | 2007-06-28 | 2007-06-28 | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| PCT/US2008/008121 WO2009005771A1 (en) | 2007-06-28 | 2008-06-27 | A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-b) indoles, its pharmacological compound and application method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531879A true JP2010531879A (ja) | 2010-09-30 |
| JP2010531879A5 JP2010531879A5 (enExample) | 2011-08-11 |
Family
ID=40226421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514847A Pending JP2010531879A (ja) | 2007-06-28 | 2008-06-27 | 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120101121A1 (enExample) |
| EP (1) | EP2161995A4 (enExample) |
| JP (1) | JP2010531879A (enExample) |
| AU (1) | AU2008271026A1 (enExample) |
| CA (1) | CA2691812A1 (enExample) |
| RU (1) | RU2338533C1 (enExample) |
| WO (1) | WO2009005771A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008302751A1 (en) | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
| WO2009120717A2 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido [3, 4-b] indoles and methods of use |
| TWI477503B (zh) | 2008-10-31 | 2015-03-21 | Medivation Technologies Inc | 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚 |
| AU2009308708B2 (en) | 2008-10-31 | 2015-11-19 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| BRPI1008020A2 (pt) | 2009-02-11 | 2016-03-15 | Sunovion Pharmaceuticals Inc | antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos |
| CA2760541A1 (en) | 2009-04-29 | 2010-11-04 | Medivation Technologies, Inc. | Pyrido[4,3-b] indoles and methods of use |
| EP2424366B1 (en) | 2009-04-29 | 2016-02-17 | Medivation Technologies, Inc. | Pyrido [4, 3-b]indoles and methods of use |
| CA2775328A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| WO2011038164A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| RU2428185C1 (ru) * | 2009-12-29 | 2011-09-10 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ ГИДРИРОВАННОГО ПИРИДО(4,3-b)ИНДОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ |
| WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US8791132B2 (en) * | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2012112963A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2014031165A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| BR112020026672A2 (pt) | 2018-06-27 | 2021-03-30 | Bioxcel Therapeutics, Inc. | Formulações de filme contendo dexmedetomidina e métodos para produzi-las |
| BR112022000992A2 (pt) | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096342A1 (en) * | 1995-10-23 | 2005-05-05 | Medivation, Inc. | Neurodegenerative disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3718657A (en) * | 1970-12-03 | 1973-02-27 | Abbott Lab | Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines |
| US6147085A (en) * | 1999-04-01 | 2000-11-14 | Neurogen Corporation | Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
-
2007
- 2007-06-28 RU RU2007124175/15A patent/RU2338533C1/ru not_active IP Right Cessation
-
2008
- 2008-06-27 CA CA002691812A patent/CA2691812A1/en not_active Abandoned
- 2008-06-27 EP EP08779878A patent/EP2161995A4/en not_active Withdrawn
- 2008-06-27 US US12/667,035 patent/US20120101121A1/en not_active Abandoned
- 2008-06-27 AU AU2008271026A patent/AU2008271026A1/en not_active Abandoned
- 2008-06-27 JP JP2010514847A patent/JP2010531879A/ja active Pending
- 2008-06-27 WO PCT/US2008/008121 patent/WO2009005771A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096342A1 (en) * | 1995-10-23 | 2005-05-05 | Medivation, Inc. | Neurodegenerative disorders |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013018911; ＢＡＣＨＵＲＩＮ，Ｓ． ｅｔ ａｌ: 'Ａｎｔｉｈｉｓｔａｍｉｎｅ ａｇｅｎｔ Ｄｉｍｅｂｏｎ ａｓ ａ ｎｏｖｅｌ ｎｅｕｒｏｐｒｏｔｅｃｔｏｒ ａｎｄ ａ ｃｏｇｎｉｔｉｏｎ ｅｎｈａｎｃｅｒ' Ａｎｎ Ｎ Ｙ Ａｃａｄ Ｓｃｉ Ｖｏｌ．９３９, 2001, ｐ．４２５-３５ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2161995A4 (en) | 2011-04-13 |
| RU2338533C1 (ru) | 2008-11-20 |
| EP2161995A1 (en) | 2010-03-17 |
| WO2009005771A1 (en) | 2009-01-08 |
| CA2691812A1 (en) | 2009-01-08 |
| US20120101121A1 (en) | 2012-04-26 |
| AU2008271026A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531879A (ja) | 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法 | |
| ES2750728T3 (es) | Uso de cannabinoides en combinación con Aripriprazol | |
| RU2106864C1 (ru) | Средство для лечения болезни альцгеймера | |
| RU2338537C2 (ru) | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| US20130029989A1 (en) | Topical treatments for pain | |
| US20080234310A1 (en) | Methods and Compositions for Slowing Aging | |
| JP2010511616A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法 | |
| KR20160147044A (ko) | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 | |
| CN106344576A (zh) | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 | |
| EP2288345B1 (en) | Psycho-pharmaceuticals | |
| RS53513B1 (sr) | Glyx-13 za upotrebu u postupku tretiranja refraktornih depresija | |
| US20070179174A1 (en) | Methods and compositions for slowing aging | |
| RS56523B1 (sr) | Tapentadol za sprečavanje i lečenje depresije i anksioznosti | |
| US20130045988A1 (en) | Combination therapy | |
| US7226949B2 (en) | Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders | |
| KR101244199B1 (ko) | 우울증 장애 치료법 | |
| KR20080105105A (ko) | 인지 장애 및 기타 장애의 치료방법 | |
| Clement et al. | Ejaculation induced by icv injection of the preferential dopamine D3 receptor agonist 7-hydroxy-2-(di-N-propylamino) tetralin in anesthetized rats | |
| Yu et al. | Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats | |
| Castro et al. | Central 5-HT2B/2C and 5-HT3 receptor stimulation decreases salt intake in sodium-depleted rats | |
| JP6889493B2 (ja) | 脳卒中からの回復のための方法および組成物 | |
| JPWO2004060400A1 (ja) | 上皮成長因子受容体を分子標的とする抗精神病薬 | |
| JP2022527865A (ja) | ストレスに対するセロトニン４受容体アゴニストの予防的有効性 | |
| EA023728B1 (ru) | Терапевтическое средство от тревожных расстройств | |
| KR20200132858A (ko) | 간질 치료제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110627 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130422 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130710 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131021 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140609 |